MS Briefs

30-Day Readmissions in Multiple Sclerosis

Mult Scler Relat Disord; ePub 2019 Mar 20; Patel, et al


 

In an age and gender-based US national retrospective analysis, overall 30-day readmission in multiple sclerosis (MS) was 10%, with higher readmission rates observed in older patients. The retrospective observational cohort study included patients hospitalized with primary discharge diagnosis of MS using 2013 Nationwide Readmission Database (NRD). Age (<40 vs >40 years) and gender-based analyses were performed using multivariable logistic regression adjusting co-variables to identify the patient/system-specific factors associated with 30-day readmission. Researchers found:

  • 30-day readmission rate in MS was 10.2% in the cohort.
  • Higher 30-day readmission was observed in patients aged >40 years due to burden of comorbidities.
  • Readmission causes were MS exacerbations, sepsis, and respiratory complications.
  • Readmission was associated with higher cost of care and longer length of stay compared to index admissions.

Patel S, SirDeshpande P, Desai R, et al. Thirty-day readmissions in multiple sclerosis: An age and gender-based US national retrospective analysis. [Published online ahead of print March 20, 2019]. Mult Scler Relat Disord. doi: 10.1016/j.msard.2019.03.012.

Recommended Reading

Cognition Concern in MS and Changes in the Brain
ICYMI Multiple Sclerosis
Genetic signature helps identify those at risk of MS
ICYMI Multiple Sclerosis
New data bolster latitude’s association with MS prevalence
ICYMI Multiple Sclerosis
Optical coherence tomography emerging as a promising biomarker for MS
ICYMI Multiple Sclerosis
Study eyes serious adverse events from long-term rituximab use in MS
ICYMI Multiple Sclerosis
Smartphone technology helps to detect, track eye changes in MS
ICYMI Multiple Sclerosis
Expert calls for more ‘ethnocentric’ research in MS
ICYMI Multiple Sclerosis
Interview with John Corboy, MD, on discontinuing disease modifying therapy in elderly patients with MS
ICYMI Multiple Sclerosis
Study launched to further evaluate the central vein sign in MS
ICYMI Multiple Sclerosis
MS researchers aim to build MRI diagnostic portfolio beyond the central vein sign
ICYMI Multiple Sclerosis